Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases

IMMU_TH Press Release

– Developing Oral Therapies with Best-in-Class Potential – – Lead Program, IMU-838, Already Advanced into Phase 2 Studies in Ulcerative Colitis and Relapsing-Remitting Multiple Sclerosis – – Proceeds of approximately USD 30 million from concurrent financing to fund clinical development pipeline – – Trading to Commence on The Nasdaq Capital Market under Symbol “IMUX” on April 15, 2019 – SAN …

Immunic Therapeutics to Present at the Needham Healthcare Conference on April 10

IMMU_TH Press Release

LINK TO WEBCAST Planegg-Martinsried, Germany, April 2, 2019 –Immunic AG, a privately held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 4:10 pm ET at the Westin Grand Central Hotel, New York. To view the live webcast, please follow …

Immunic Therapeutics to Participate in Investor and Medical Conferences in March

IMMU_TH Press Release

  Planegg-Martinsried, Germany, February 28, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced that management will participate in the following conferences in March: March 6-9: 14th Congress of ECCO (European Crohn’s and Colitis Organization) in Copenhagen. Immunic will host Key Opinion Leader meetings on March 7 and 8. Attending from the company will be Andreas …

Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis

IMMU_TH Press Release

  Planegg-Martinsried, Germany, February 26, 2019 – Immunic AG (Immunic), a privately held clinical-stage biotechnology company, today announced enrollment of the first patient in a phase 2 clinical study of IMU-838 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). IMU-838 is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by …

Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11

IMMU_TH Press Release

Link to Webcast   Planegg-Martinsried, Germany, February 6, 2019 – Immunic AG (Immunic), a privately-held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present at the BIO CEO & Investor Conference on Monday, February 11, 2019 at 9:45 am ET at the New York Marriott Marquis, in the Chelsea room. To view the live webcast, please follow this link: …

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

IMMU_TH Press Release

Link to Conference Call Webcast Link to Filed Form S-4 (sec.gov)   Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets Lead Program, IMU-838, an Orally Available, Small Molecule Inhibitor of DHODH, Already Advanced into Phase 2 Studies in Ulcerative Colitis  Companies to Host Conference Call to Discuss Transaction at …

Immunic enters into a global option and license agreement with Daiichi Sankyo

IMMU_TH Press Release

Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease IMU-856 is a new oral treatment option for ulcerative colitis and Crohn’s disease Daiichi Sakyo Co., Ltd. granted Immunic AG an exclusive option to in-license the drug development program when entering phase 1 clinical development IMU-856 uses an undisclosed new …

Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Colitis

IMMU_TH Press Release

First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor Multiple sites have already been initiated in the US and first patient has been enrolled Several approvals for the ‘CALDOSE-1’ study from regulatory agencies have already been granted in European countries as well and Immunic expects patients to be enrolled in …

FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis

IMMU_TH Press Release

FDA has granted IND approval for Immunic’s oral investigational drug IMU-838 Active IND allows Immunic to proceed with Phase 2 clinical trial (CALDOSE-1) Patients with active ulcerative colitis will be treated following randomization to multiple doses of IMU-838 or placebo Planegg-Martinsried, Germany, January 11th, 2017 – Immunic AG (Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, …

Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838

IMMU_TH Press Release

Two phase 1 studies for IMU-838 in healthy volunteers have been completed Compound was safe and well tolerated at all doses tested New dosing regimen was determined allowing safe administration of higher doses Planegg-Martinsried, Germany, December 12th, 2017 – Immunic AG (Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, today announced that it has completed its …